2020年10月08日Mirati Therapeutics Inc.（MRTX）今日股票价格多少？

　　截止2020年10月08日22时11分Mirati Therapeutics Inc.（MRTX）最新价180.9100，涨跌额0.7400，涨跌幅0.41%，昨收180.1700，今开182.4400，最高182.6800，最低179.7500，成交量12798手。

　　报告日期2020年03月31日，年结日12-31，币种美元，Mirati Therapeutics Inc.（MRTX）收入26.70万，收入增长-78.54%，毛利26.70万，毛利增长-78.54%，归母净利润-8665.50万，归母净利润增长-111.81%，基本每股收益-2.02，稀释每股收益-2.02，销售毛利率100%，销售净利率-3.25%。

　　Mirati Therapeutics Inc.（MRTX）2020年01月01日至2020年03月31日License and collaboration revenues金额（USD）26.70万，比率100%。

　　Mirati Therapeutics Inc.（MRTX）主要指标（币种：美元）：截止2020年03月31日Mirati Therapeutics Inc.（MRTX）市盈率（TTM）-29.5805255515749，市净率（MRQ）7.62481989147032，每股收益（TTM）-5.93456817738442，每股净资产15.036420745919，每股股息（USD）--，周息率--%，收入总额26.70万，收入总额同比-78.5369774919614%，归母净利润-8665.50万，归母净利润同比-111.808271411811%，毛利率100%，净利率-32455.0561797753%，总股本4364.24万，总市值（USD）50.04亿。

　　报告日期2020年03月31日，年结日12-31，币种美元，Mirati Therapeutics Inc.（MRTX）净资产收益率-16.69%，总资产净利率-15.13%。

　　公司介绍： Mirati Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer. This approach is transforming the treatment of patients with cancer by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and migration. Company's precision oncology programs seek to treat the patients most likely to benefit from targeted oncology treatments and is driven by drugs that target very specific genetic mutations, directed by genomic tests that identify patients who carry those driver mutations. The company's immuno-oncology programs are novel small molecule drugs designed to enhance and expand the efficacy of checkpoint inhibitors when given in combination. In addition to clinical programs, company has an active discovery research program focused on novel oncology targets. The promise of these approaches includes potentially better patient outcomes, more efficient cancer treatment and faster drug development.

　　本站数据均为参考数据，不具备市场交易依据。